The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome

    Jana Figurová, Ingrid Dravecká, Jana Petríková, Martin Javorský, Ivica Lazúrová
    Image of study
    TLDR Metformin effectively improves metabolic symptoms in women with PCOS, while alfacalcidiol does not have a significant impact.
    In the 2017 study involving 39 women with polycystic ovary syndrome (PCOS), the effects of alfacalcidiol, metformin, and their combination on metabolic disturbances were evaluated over 6 months. The study found that metformin alone significantly reduced body weight, BMI, waist circumference, total body fat, and serum glucose levels. The combination of metformin and alfacalcidiol led to a significant reduction in waist circumference but did not significantly affect other metabolic parameters. Alfacalcidiol alone did not result in significant changes, except for a slight, non-significant increase in HDL cholesterol. The study concluded that vitamin D supplementation by itself does not significantly impact metabolic parameters in women with PCOS and that metformin is the most effective treatment for metabolic changes associated with PCOS.
    View this study on →

    Cited in this study